etarfolatide
Small moleculeexperimentalImaging agent
Technetium (99mTc) etarfolatide is an investigational non-invasive, folate receptor-targeting companion imaging agent that is being developed by Endocyte. Etarfolatide consists of a small molecule targeting the folate receptor and an imaging agent, which is based on technetium-99m. This companion imaging agent identifies cells expressing the folate receptor, including cancer and inflammatory cells. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00511485)
Timeline
Indications
Mechanism of action
- Folate receptor alphaBINDING AGENT
FOLR1 binding agent
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@H](CNC(=O)CC[C@@H](NC(=O)c1ccc(NCc2c[nH]c3ncnc(=O)c-3n2)cc1)C(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O- Mol. weight
- 730.72 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTechnetium (99mTc) etarfolatide ↗
- ChEMBLCHEMBL4297280 ↗
Also known as
- etarfolatide
- etarfolatide
- etarfolatide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01953536 | Phase 2 | Apr 1, 2014 | Endocyte |
| NCT01748864 | Phase 1 | Apr 1, 2013 | Endocyte, Horizon Oncology Research, Inc. |
| NCT00511485 | Phase 2 | Aug 1, 2007 | Endocyte |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Endocyte | For profit | 3 | 3 | 2 | 2007 |
| Horizon Oncology Research, Inc. | For profit | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1